Meaningful improvement in walking performance after Botulinum Neurotoxin A (BoNT-A) in chronic spastic patients.

BACKGROUND: Botulinum neurotoxin A (BoNT-A) may reduce lower limb spasticity but its role in improving walking ability remains to be established. OBJECTIVE: To investigate the efficacy of simultaneous BoNT-A injections into several targeted spastic muscles of different joints on gait speed and on fu...

Descripción completa

Detalles Bibliográficos
Publicado en:NeuroRehabilitation Vol. 34; no. 1; pp. 185 - 193
Autores principales: Cioncoloni, David, Taddei, Sabrina, Bielli, Silvia, Annunziata, Pasquale, Mazzocchio, Riccardo
Formato: research tables/charts Journal Article
Publicado: Sage Publications Inc. 2014
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:BACKGROUND: Botulinum neurotoxin A (BoNT-A) may reduce lower limb spasticity but its role in improving walking ability remains to be established. OBJECTIVE: To investigate the efficacy of simultaneous BoNT-A injections into several targeted spastic muscles of different joints on gait speed and on functional gains in gait performance in chronic stroke and MS patients. METHODS: Twenty patients affected by stroke or multiple sclerosis were tested before, one and three months after BoNT-A administration. Gait was evaluated by the 10 Meter Walk Test; patients were stratified into functional ambulation classes accordingly. Spasticity was assessed using the modified Ashworth Scale. RESULTS: At final assessment, spasticity was reduced in hip adductors and ankle plantar-flexors, gait speed improved and, 1/3rd of patients transitioned to a higher ambulation class. The pre-post difference in Level of Spasticity of the hips was a predictor for an increase in gait speed. CONCLUSIONS: A meaningful improvement in walking performance can be obtained in chronic spastic patients after BoNT-A injection into several muscles, specifically the hip adductors.